Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB Study of Pembrolizumab in Combination With Pemetrexed and Oxaliplatin in Patients With Chemo-Refractory Metastatic Colorectal Cancer

NCT03626922 is registered in ClinicalTrials.gov with NSABP Foundation Inc as lead sponsor.

NCT NCT03626922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03626922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB Study of Pembrolizumab in Combination With Pemetrexed and Oxaliplatin in Patients With Chemo-Refractory Metastatic Colorectal Cancer
Lead sponsor
NSABP Foundation Inc
Phase
Phase 1
Overall status
Unknown status
Start date
May 15, 2019
Completion date
November 30, 2022
Enrollment
33 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer